ArticleBiofabrication2023
Gelatin methacryloyl and Laponite bioink for 3D bioprinted organotypic tumor modeling.
Erratum issuedOpen access · hybridAbstract read
In one paragraph
Article in Biofabrication, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers.
0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 32 citations in OpenAlex.
- 3D Bioprinting for Tumor Microenvironment Reconstruction: Advances, Challenges, and Future Perspectives.Biotechnology journal · 2026Review
- Review
- Facile Single-Nanocomposite 4D Bioprinting of Dynamic Hydrogel Constructs with Thickness-Controlled Gradient.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Bioprinted platform for parallelized screening of engineered microtissues in vivo.Cell stem cell · 2025Article
- Injectable hydrogels based on mussel-inspired nanocomposite microspheres for non-compressible intra-abdominal hemorrhage control.Theranostics · 2025Article
- Functionalized 3D-printed GelMA/Laponite hydrogel scaffold promotes BMSCs recruitment through osteoimmunomodulatory enhance osteogenic via AMPK/mTOR signaling pathway.Materials today. Bio · 2024Article
- Recent advances and applications of artificial intelligence in 3D bioprinting.Biophysics reviews · 2024Review
- Nanobioactive Blood-Derived Shear-Thinning Biomaterial for Tissue Engineering Applications.Applied materials today · 2024Article
- Addition of Laponite to gelatin methacryloyl bioinks improves the rheological properties and printability to create mechanically tailorable cell culture matrices.APL bioengineering · 2024Article
- Biofabrication and biomanufacturing in Ireland and the UK.Bio-design and manufacturing · 2024Review
- Injectable Nanoengineered Adhesive Hydrogel for Treating Enterocutaneous Fistulas.Acta biomaterialia · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
21 authors at 5 institutions in 3 countries.
Natan Roberto de BarrosTerasaki Institute for Biomedical Innovation (TIBI), 1018 Westwood Blvd, Los Angeles, CA 90024, United States of America.ORCID 0000-0001-8689-4110
Alejandro GomezTerasaki Institute for Biomedical Innovation (TIBI), 1018 Westwood Blvd, Los Angeles, CA 90024, United States of America.
Menekse ErmisTerasaki Institute for Biomedical Innovation (TIBI), 1018 Westwood Blvd, Los Angeles, CA 90024, United States of America.
Natashya FalconeTerasaki Institute for Biomedical Innovation (TIBI), 1018 Westwood Blvd, Los Angeles, CA 90024, United States of America.
Reihaneh HaghniazTerasaki Institute for Biomedical Innovation (TIBI), 1018 Westwood Blvd, Los Angeles, CA 90024, United States of America.
Patric YoungTerasaki Institute for Biomedical Innovation (TIBI), 1018 Westwood Blvd, Los Angeles, CA 90024, United States of America.
Yaqi GaoTerasaki Institute for Biomedical Innovation (TIBI), 1018 Westwood Blvd, Los Angeles, CA 90024, United States of America.
Albert-Fred AquinoDepartment of Biology, California State University, Northridge, CA 91330, United States of America.
Siyuan LiTerasaki Institute for Biomedical Innovation (TIBI), 1018 Westwood Blvd, Los Angeles, CA 90024, United States of America.
Siyi NiuTerasaki Institute for Biomedical Innovation (TIBI), 1018 Westwood Blvd, Los Angeles, CA 90024, United States of America.
RunRun ChenTerasaki Institute for Biomedical Innovation (TIBI), 1018 Westwood Blvd, Los Angeles, CA 90024, United States of America.
Shuyi HuangTerasaki Institute for Biomedical Innovation (TIBI), 1018 Westwood Blvd, Los Angeles, CA 90024, United States of America.
Yangzhi ZhuTerasaki Institute for Biomedical Innovation (TIBI), 1018 Westwood Blvd, Los Angeles, CA 90024, United States of America.
Payam EliahooDepartment of Biomedical Engineering, University of Southern California, Los Angeles, CA 90088, United States of America.
Arthur SunTerasaki Institute for Biomedical Innovation (TIBI), 1018 Westwood Blvd, Los Angeles, CA 90024, United States of America.
Danial KhorsandiTerasaki Institute for Biomedical Innovation (TIBI), 1018 Westwood Blvd, Los Angeles, CA 90024, United States of America.
Jinjoo KimTerasaki Institute for Biomedical Innovation (TIBI), 1018 Westwood Blvd, Los Angeles, CA 90024, United States of America.
Jonathan KelberDepartment of Biology, California State University, Northridge, CA 91330, United States of America.ORCID 0000-0002-4606-1445
Ali KhademhosseiniTerasaki Institute for Biomedical Innovation (TIBI), 1018 Westwood Blvd, Los Angeles, CA 90024, United States of America.ORCID 0000-0002-2692-1524
Han-Jun KimTerasaki Institute for Biomedical Innovation (TIBI), 1018 Westwood Blvd, Los Angeles, CA 90024, United States of America.ORCID 0000-0001-9238-7238
Bingbing LiTerasaki Institute for Biomedical Innovation (TIBI), 1018 Westwood Blvd, Los Angeles, CA 90024, United States of America.ORCID 0000-0001-6140-4189
California State University, Northridge · USTerasaki Foundation · USBaylor University · USKorea University · KRUniversity of Southern California · US
Funding
SPATIOTEMPORAL MECHANISMS OF EIF5A1/2-MEDIATED METASTASIS IN TRIPLE-NEGATIVE BREAST CANCERSC1GM121182 · NIGMS · CALIFORNIA STATE UNIVERSITY NORTHRIDGE · PI KELBER, JONATHAN · 2017 to 2024
$3.2MDrug eluting injectable biomaterials for next generation chemoembolizationR01CA257558 · NCI · MAYO CLINIC ARIZONA · PI KHADEMHOSSEINI, ALI, OKLU, RAHMI · 2021 to 2025
$3.2MHemorrhage control in the irreversible anticoagulated patientR01HL137193 · NHLBI · MAYO CLINIC ARIZONA · PI OKLU, RAHMI · 2017 to 2021
$3.0MTreatment of arterial aneurysms using an injectable biomaterialR01HL140951 · NHLBI · MAYO CLINIC ARIZONA · PI KHADEMHOSSEINI, ALI, OKLU, RAHMI · 2018 to 2021
$2.6MHealing enterocutaneous fistulas using bioengineered biomaterialsR01DK130566 · NIDDK · MAYO CLINIC ARIZONA · PI KHADEMHOSSEINI, ALI, OKLU, RAHMI · 2022 to 2025
$2.2MNCI NIH HHS R01 CA257558NHLBI NIH HHS R01 HL137193NHLBI NIH HHS R01 HL140951NIDDK NIH HHS R01 DK130566NIGMS NIH HHS SC1 GM121182
Abstract
Three-dimensional (3D)
Indexed as
BioprintingNeoplasmsBiological FactorsGelatinHumansHydrogelsMethacrylatesPrinting, Three-DimensionalSilicatesTissue EngineeringTissue ScaffoldsTumor MicroenvironmentBiological FactorsGelatingelatin methacryloylHydrogelslaponiteMethacrylatesSilicates3D bioprintinggelatin methacryloylnanoengineered composite hydrogelorganotypicpancreatic cancersilicate nanoplatelet
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.